Leber Congenital Amaurosis (LCA) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Leber Congenital Amaurosis (LCA) – Drugs In Development, 2024 report and make more profitable business decisions.
Leber congenital amaurosis (LCA) is a genetic eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
The Leber Congenital Amaurosis (LCA) drugs in development market research report provide comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Leber Congenital Amaurosis (LCA) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Leber Congenital Amaurosis (LCA) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Leber Congenital Amaurosis (LCA) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Leber Congenital Amaurosis (LCA) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Atsena Therapeutics IncCase Western Reserve University
Editas Medicine Inc
Frontera Therapeutics Inc
Generation Bio Co
Hubble Therapeutics Inc
HuidaGene Therapeutics Co Ltd
Innostellar Biotherapeutics Co Ltd
IVERIC bio Inc
LuxFiat Therapeutics LLC
MeiraGTx Holdings Plc
National Eye Institute
Ocugen Inc
Odylia Therapeutics Inc
Opus Genetics Inc
ProQR Therapeutics NV
University of Florida
Variant
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Leber Congenital Amaurosis (LCA) reports